중앙백신
072020KOSDAQ62.3 / 100
Reference Date: 2026-09-08
Company InformationBased on 2025 Annual Report
Business Overview
Central Vaccine is a company specializing in the development and production of animal vaccines and biological products, focusing on disease prevention and control in the livestock industry. Recent outbreaks of African Swine Fever and Highly Pathogenic Avian Influenza have increased demand for vaccines, necessitating the development of new products to counteract the diminishing efficacy of existing ones. The company is expanding into new markets, including China and Brazil, to broaden its global presence.
Number of Employees
194people
Average Salary
57.1M KRW
Score Calculation Basis
Detailed Financial Score
In line with industry avg
Lower than industry avg (good)
Below industry avg
Half of industry avg (excellent)
Avg ▲8.3% (2-year basis)
Avg ▼2.6% (2-year basis)
Avg ROE 6.3% (declining, 3yr)
Detailed News Sentiment
- Positive중앙백신, 대신증권과 유동성 공급계약 체결
중앙백신이 대신증권과의 계약을 통해 유동성 확보로 인해 주가 활성화 기대.
Detailed Momentum
52w lower range (38%)
1m 0.22% (flat)
Volume decreasing
Detailed Disclosure
- Neutral유동성공급계약의체결2026-08-18
- Neutral반기보고서 (2026.06)2026-08-14
